Evidence map›Paper›PMID 37715113›Full record

ArticleBMC cancer2023

The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy.

Tsung-Han Tsai, Po-Jung Su, Shih-Yu Huang, Ming-Chun Kuo, Chang-Ting Lin, Chia-Che Wu, Hao-Lun Luo, Chien-Hsu Chen, Chih-Chi Chou, Ting-Ting Liu and 3 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Tsung-Han TsaiDivision of Hematology Oncology, Department of Internal Medicine, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, No.123, Dapi Rd., Niaosong Dist, Kaohsiung City, 833, Taiwan.
Po-Jung SuDivision of Hematology Oncology, Chang Gung Memorial Hospital at Linkou and College of Medicine, Chang Gung University, Tao-Yuan, Kaohsiung City, Taiwan.
Shih-Yu HuangDivision of Hematology Oncology, Department of Internal Medicine, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, No.123, Dapi Rd., Niaosong Dist, Kaohsiung City, 833, Taiwan.
Ming-Chun KuoDivision of Hematology Oncology, Department of Internal Medicine, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, No.123, Dapi Rd., Niaosong Dist, Kaohsiung City, 833, Taiwan.
Chang-Ting LinDivision of Hematology Oncology, Department of Internal Medicine, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, No.123, Dapi Rd., Niaosong Dist, Kaohsiung City, 833, Taiwan.
Chia-Che WuDivision of Hematology Oncology, Department of Internal Medicine, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, No.123, Dapi Rd., Niaosong Dist, Kaohsiung City, 833, Taiwan.
Hao-Lun LuoDepartment of Urology, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung City, Taiwan.
Chien-Hsu ChenDepartment of Urology, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung City, Taiwan.
Chih-Chi ChouDepartment of Pathology, College of Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University, Kaohsiung City, Taiwan.
Ting-Ting LiuDepartment of Pathology, College of Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University, Kaohsiung City, Taiwan.
Chun-Chieh HuangDepartment of Radiation Oncology, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung City, Taiwan.
Kai-Lung TsaiDepartment of Colorectal Surgery, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung City, Taiwan.
Yu-Li SuDivision of Hematology Oncology, Department of Internal Medicine, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, No.123, Dapi Rd., Niaosong Dist, Kaohsiung City, 833, Taiwan. yolisu@mac.com.
Kaohsiung Chang Gung Memorial Hospital · TWChang Gung University · TW

Funding

Chang Gung Memorial Hospital, Kaohsiung, Taiwan CPRPG8J0011, CPRPG8J0012
6 · The paper itself

Abstract

backgroundWhile the treatment guidelines have been established for pure urothelial carcinoma (pUC), patients with variant type urothelial carcinoma (vUC) face limited effective treatment options. The effectiveness of immune checkpoint inhibitors (ICI) in patients with vUC remains uncertain and necessitates additional research.

methodWe conducted a retrospective, multicenter study to explore the effectiveness of ICI in patients with pUC or vUC in Taiwan. We evaluated the overall response rate (ORR) through univariate logistic regression analysis and examined the overall survival (OS) and progression-free survival (PFS) using Kaplan-Meier analysis. Additionally, we employed univariate and multivariate Cox proportional hazards models to analyze the data.

resultA total of 142 patients (116 pUC, 26 vUC) were included in our final analysis. The ORR was marginally higher in patients with pUC compared to those with vUC (34.5% vs. 23.1%, p = 0.26). Among all patients, 12.9% with pUC achieved a complete response (CR) after ICI treatment, while no vUC cases achieved CR (p = 0.05). There were no significant differences in PFS (median 3.6 months vs. 4.1 months, p = 0.34) or OS (median 16.3 months vs. 11.0 months, p = 0.24) when comparing patients with pUC or vUC. In the subgroup analysis, patients with pUC who underwent first-line ICI treatment exhibited significantly improved OS compared to those with vUC (24.6 months vs. 9.1 months, p = 0.004).

conclusionThe use of ICI as monotherapy is a feasible and effective treatment approach for patients with metastatic vUC.

Indexed as

Carcinoma, Transitional CellUrinary Bladder NeoplasmsHumansImmune Checkpoint InhibitorsPrognosisRetrospective StudiesImmune Checkpoint InhibitorsImmune checkpoint inhibitorsMetastatic urothelial carcinomaReal-world dataVariant histology

Identifiers

PMID37715113
PMCPMC10504763
OpenAlexW4386773854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.